cytarabine and s 1033
cytarabine has been researched along with s 1033 in 7 studies
Research
Studies (7)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cleverley, J | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Caruso, M; de Campos-Lima, PO; Ghani, K; Naud, JS | 1 |
| Baldus, CD; Bock, J; Hofmann, WK; Kühl, AA; Mochmann, LH; Neumann, M; Nowak, V; Ortiz-Tanchez, J; von der Heide, EK | 1 |
| Iriyama, N; Kawaguchi, T; Kirito, K; Kizaki, M; Shimoda, K; Takahashi, N | 1 |
| Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W | 1 |
Reviews
2 review(s) available for cytarabine and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Cytarabine; Dasatinib; Drug Monitoring; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2020 |
Other Studies
5 other study(ies) available for cytarabine and s 1033
| Article | Year |
|---|---|
American Society of Clinical Oncology--42nd annual meeting. Poster presentations on leukemia and cytotoxic chemotherapy. 2-6 June 2006, Atlanta, GA, USA.
Topics: Clinical Trials as Topic; Cytarabine; Drug Combinations; Gossypol; Humans; Leukemia; Mastocytosis, Systemic; Molecular Structure; Pyrimidines; Pyrrolidines; Thionucleotides; Thymine; Trifluridine; Uracil | 2006 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy.
Topics: Benzamides; Cytarabine; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thymidine; Tumor Cells, Cultured | 2012 |
ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Dasatinib; DNA Repair; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; K562 Cells; Mesoderm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Thiazoles; Trans-Activators; Transcriptional Regulator ERG | 2014 |
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Pyrimidines; Remission Induction; Transplantation, Autologous | 2020 |